Literature DB >> 7899982

Experimental model of posterolateral spinal arthrodesis in sheep. Part 2. Application of the model: evaluation of vertebral fusion obtained with coral (Porites) or with a biphasic ceramic (Triosite).

P Guigui1, P Y Plais, B Flautre, E Viguier, M C Blary, D Chopin, F Lavaste, P Hardouin.   

Abstract

OBJECTIVES: The authors evaluated two bone substitutes in a posterolateral spinal arthrodesis (PSA) model in sheep: coral porites (99% calcium carbonate, Biocoral, Inoteb, France) and a biphasic ceramic (BCP) (65% hydroxyapatite and 35% B tricalcium phosphate, Triosite, Zimmer International). SUMMARY OF BACKGROUND DATA: Bone substitutes would be of great interest for PSA. Previous trials began with two kinds of biomaterials: natural coralline calcium carbonate, and phosphate calcium ceramic.
METHODS: A lumbar PSA was performed in 11 sheep (coral group) and in 9 sheep (BCP group). Sacrifice and biomechanical tests were performed after 1 year.
RESULTS: A large decrease of flexibility in all directions was obtained with both coral PSA and BCP PSA similarly to autologous graft. No nonfusion case was observed.
CONCLUSION: In conditions close to the human surgery, a PSA can be obtained using either coral porites or BCP as bone substitutes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7899982

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  2 in total

1.  Spinal fusion using an autologous growth factor gel and a porous resorbable ceramic.

Authors:  William R Walsh; Andreas Loefler; Sean Nicklin; Doug Arm; Ralph E Stanford; Yan Yu; Richard Harris; R M Gillies
Journal:  Eur Spine J       Date:  2004-03-18       Impact factor: 3.134

2.  Correlative radiological, self-assessment and clinical analysis of evolution in instrumented dorsal and lateral fusion for degenerative lumbar spine disease. Autograft versus coralline hydroxyapatite.

Authors:  Panagiotis Korovessis; Georgios Koureas; Spyridon Zacharatos; Zisis Papazisis; Elias Lambiris
Journal:  Eur Spine J       Date:  2005-03-24       Impact factor: 3.134

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.